X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    In An FDA First, Cardiac Gene Therapy Given RMAT Status

    Bacterial Compound Can Help Halt Influenza Virus Cloning

    ABPI In UK Sees Possibility of Revenue Clawback Rate Rise

    Pembrolizumab And Chemo-Boon To Endometrial Cancer Survival

    Soon To Become A Reality- A Damaged Kidney Restoration

    A New Healer Antibody Medicine For Fatty Liver Disease

    Clinical Trials Information System Now A Single Point Check

    Singapore Research & Innovation Gets A Push Of $50mn Funding

    Cancer Spread Given More Thrust Because of Role of Actin

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    In An FDA First, Cardiac Gene Therapy Given RMAT Status

    Bacterial Compound Can Help Halt Influenza Virus Cloning

    ABPI In UK Sees Possibility of Revenue Clawback Rate Rise

    Pembrolizumab And Chemo-Boon To Endometrial Cancer Survival

    Soon To Become A Reality- A Damaged Kidney Restoration

    A New Healer Antibody Medicine For Fatty Liver Disease

    Clinical Trials Information System Now A Single Point Check

    Singapore Research & Innovation Gets A Push Of $50mn Funding

    Cancer Spread Given More Thrust Because of Role of Actin

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

In An FDA First, Cardiac Gene Therapy Given RMAT Status

Content Team by Content Team
13th February 2023
in FDA Approvals, News

The Regenerative Medicine Advanced Therapies designation of RP-A501, which happens to be an adeno-associated virus-based gene therapy when it comes to the treatment of Danon disease, has been granted by the US Food and Drug Administration.

According to Dr. Gaurav Shah, one of the chief executives of a pharma firm, RP-501 is the first gene therapy related to the heart that has received the designation of RMAT from the FDA. Due to this designation, there shall come added benefits of an intensive FDA guidance and also a quick review of the program’s development.

The RMAT designation has come into play in order to quicken drug development and also review the process when it comes to pipeline products that are promising, such as gene therapies. It is well to be noted that a regenerative gene therapy is a fit for the RMAT designation if it is focused on treating, modifying, reversing, or curing a serious or life-threatening condition, and the preliminary data suggests that the therapy or the drug, both have the potential to take care of the unmet medical needs of the condition and the disease.

Danon disease happens to be a genetic, rare disease that is caused by a mutation in the gene encoding lysosome-associated membrane protein 2, or LAMP-2, which is a crucial autophagy mediator. This, ultimately, amounts to heart failure and is mostly fatal to the male patients. Besides the cardiac transplant, which is not regarded as curative, there are as of now no disease-altering treatments that can be looked into.

The Phase I trial

This RMAT designation has been granted based on the favourable efficacy and safety data that one could get from the Phase I RP-A501 clinical trial. The inferences from the phase I trial give away one of the most absolute investigational gene therapy datasets in the case of any cardiac condition.

The toleration level of RP-A501 was high in the trial. The evidence also showed a restored deficient LAMP2 protein expression and also a durable enhancement of stabilisation in terms of clinical parameters.

It is also crucial to note here that stabilisation as well as improvements in the brain natriuretic peptide and New York Heart Association class are in complete contrast to the rise in BNP and NYHA class deterioration that has been observed in the sample given in the cases of adolescent and paediatric natural histories of patients.

A Phase II trial is also in the works for this year’s second quarter. This is planned as a single-arm, open-label trial with a composite endpoint based on a biomarker and also a natural history comparator.

Previous Post

Bacterial Compound Can Help Halt Influenza Virus Cloning

Related Posts

News

Bacterial Compound Can Help Halt Influenza Virus Cloning

11th February 2023
IPR Data Management

Dustiness of HPAPI In Sealed System Can Be Predicted Now

10th February 2023
IPR Data Management

Identifying The Tumour With Fluorescence Guided Surgery

10th February 2023
News

OA Progression Gauged By Use of Plasma Proteomics Signature

10th February 2023
IPR Data Management

30% Lesser Side Effects, Thanks To The DNA Medication Pass

10th February 2023
Usual Pharma Compliance Issues Noted In FDA Warning Letters
News

Twelve Digit National Drug Code Gets Proposed By The FDA

8th February 2023

Latest News

FDA Approvals

In An FDA First, Cardiac Gene Therapy Given RMAT Status

13th February 2023
News

Bacterial Compound Can Help Halt Influenza Virus Cloning

11th February 2023
IPR Data Management

Dustiness of HPAPI In Sealed System Can Be Predicted Now

10th February 2023
IPR Data Management

Identifying The Tumour With Fluorescence Guided Surgery

10th February 2023
News

OA Progression Gauged By Use of Plasma Proteomics Signature

10th February 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In